Hemophilia A Market

Hemophilia A Market

The market size of Hemophilia A was found to be USD 6,266 Million in 2017.The total diagnosed and treated prevalent population of Hemophilia A was found to be 38,212 in 2017 (in the 7 MM). 

The popularity of Gene Therapy, Development of Novel Treatments with an extended half-life, and Increased Focus on Prophylactic Treatment are some of the leading factors expected to drive the Hemophilia A market in the coming years. 

The key players in the Hemophilia A market include Biomarin Pharmaceutical, Novo Nordisk, Sanofi, Pfizer, Catalyst Biosciences, OPKO Biologics, Spark Therapeutics, Sangamo therapeutics and others. 

For more details visit:


#hemophiliaA #medicine #treatment #prophylaxis #hemophilia #patients #geneticdisorder #geneticdisease